Literature DB >> 12743671

Cytochrome P4502E1 (CYP2E1) expression in peripheral blood lymphocytes: evaluation in hepatitis C and diabetes.

Vincent Haufroid1, Danuta Ligocka, Martin Buysschaert, Yves Horsmans, Dominique Lison.   

Abstract

OBJECTIVE: Cytochrome P4502E1 (CYP2E1) is expressed in human peripheral blood lymphocytes (PBLs), and previous reports have suggested the possibility of using this readily available tissue as a reporter of CYP2E1 status. To further explore the relevance of this approach we assessed CYP2E1 expression in PBLs in two contrasting conditions, chronic hepatitis C and insulin-dependent diabetes (IDD), illustrating an organ and a systemic disease, respectively.
METHODS: Total RNA was isolated from extracted PBLs (hepatitis C patients + IDD) and by percutaneous needle biopsy (hepatitis C patients only). Gene expression for CYP2E1 was determined by real-time reverse-transcription polymerase chain reaction. Histological changes in liver tissue were assessed according to Ludwig's criteria.
RESULTS: In patients with chronic hepatitis C a clear relationship was found between CYP2E1 expression in the liver and the progression of hepatic disease (both lobular inflammation and fibrosis indices), and observed variations were consistent with the preferential distribution of CYP2E1 in the lobular zone. No effect of the liver disease was, however, found at the PBL level. A statistically significant increase in mean CYP2E1 expression level was observed in the lymphocytes from poorly controlled IDD subjects compared to controls.
CONCLUSIONS: Taken together, our data indicate that the measurement of CYP2E1 expression in PBLs is not useful in liver diseases. However, in a systemic condition (IDD) this measurement can be proposed for monitoring the CYP2E1 induction in a relatively noninvasive manner. This tool should therefore be further validated in clinical field or experimental studies for CYP2E1 phenotyping purposes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12743671     DOI: 10.1007/s00228-003-0566-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  Relationship between mRNA levels quantified by reverse transcription-competitive PCR and metabolic activity of CYP3A4 and CYP2E1 in human liver.

Authors:  A Sumida; K Kinoshita; T Fukuda; H Matsuda; I Yamamoto; T Inaba; J Azuma
Journal:  Biochem Biophys Res Commun       Date:  1999-08-27       Impact factor: 3.575

Review 2.  Drug metabolizing enzymes in lymphocytes.

Authors:  J L Raucy; M Ingelman-Sundberg; S Carpenter; A Rannug; A Rane; M Franklin; M Romkes
Journal:  J Biochem Mol Toxicol       Date:  1999       Impact factor: 3.642

3.  Real-time quantification of cytochrome P4502E1 mRNA in human peripheral blood lymphocytes by reverse transcription-PCR: method and practical application.

Authors:  V Haufroid; F Toubeau; A Clippe; M Buysschaert; J L Gala; D Lison
Journal:  Clin Chem       Date:  2001-06       Impact factor: 8.327

4.  CYP2E1 expression in human lymphocytes from various ethnic populations.

Authors:  J L Raucy; E D Schultz; M C Kearins; S Arora; D E Johnston; J L Omdahl; L Eckmann; S P Carpenter
Journal:  Alcohol Clin Exp Res       Date:  1999-12       Impact factor: 3.455

5.  Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression.

Authors:  Kimberley J Woodcroft; Mikehl S Hafner; Raymond F Novak
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

6.  Independent patterns of cytochrome P450 gene expression in liver and blood in patients with suspected liver disease.

Authors:  N Finnström; M Thörn; L Lööf; A Rane
Journal:  Eur J Clin Pharmacol       Date:  2001-08       Impact factor: 2.953

7.  Lymphocyte cytochrome P450-CYP2E1 expression in human IDDM subjects.

Authors:  M P Hannon-Fletcher; M J O'Kane; K W Moles; Y A Barnett; C R Barnett
Journal:  Food Chem Toxicol       Date:  2001-02       Impact factor: 6.023

8.  Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity.

Authors:  J L Raucy; E D Schultz; M R Wester; S Arora; D E Johnston; J L Omdahl; S P Carpenter
Journal:  Drug Metab Dispos       Date:  1997-12       Impact factor: 3.922

9.  Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype.

Authors:  H Powell; N R Kitteringham; M Pirmohamed; D A Smith; B K Park
Journal:  Pharmacogenetics       Date:  1998-10

10.  Stabilization of cytochrome P450j messenger ribonucleic acid in the diabetic rat.

Authors:  B J Song; T Matsunaga; J P Hardwick; S S Park; R L Veech; C S Yang; H V Gelboin; F J Gonzalez
Journal:  Mol Endocrinol       Date:  1987-08
View more
  5 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

Review 2.  Antioxidant and anti-inflammatory effects of exercise in diabetic patients.

Authors:  Saeid Golbidi; Mohammad Badran; Ismail Laher
Journal:  Exp Diabetes Res       Date:  2011-10-11

3.  HCV core protein uses multiple mechanisms to induce oxidative stress in human hepatoma Huh7 cells.

Authors:  Alexander V Ivanov; Olga A Smirnova; Irina Y Petrushanko; Olga N Ivanova; Inna L Karpenko; Ekaterina Alekseeva; Irina Sominskaya; Alexander A Makarov; Birke Bartosch; Sergey N Kochetkov; Maria G Isaguliants
Journal:  Viruses       Date:  2015-05-29       Impact factor: 5.048

4.  Gene expression profiling in the type 1 diabetes rat diaphragm.

Authors:  Erik van Lunteren; Michelle Moyer
Journal:  PLoS One       Date:  2009-11-13       Impact factor: 3.240

5.  Targeted CYP2E1 quantification and its correlation to currently acceptable clinical biochemical indices.

Authors:  Anuar Zaini; Iekhsan Othman; Christina Gertrude Yap
Journal:  J Biol Res (Thessalon)       Date:  2016-06-30       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.